Neoadjuvant PD-1 Blockade for Elderly Esophageal Squamous Cell Carcinoma (BLESS) - Trial NCT06385730
Access comprehensive clinical trial information for NCT06385730 through Pure Global AI's free database. This Phase 2 trial is sponsored by Shanghai Chest Hospital and is currently Not yet recruiting. The study focuses on Esophageal Cancer. Target enrollment is 60 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.
Study Focus
Sponsor & Location
Shanghai Chest Hospital
Timeline & Enrollment
Phase 2
May 01, 2024
May 01, 2027
Primary Outcome
MPR rate
Summary
The investigators will conduct a prospective phase 2 study to evaluate the efficacy and
 safety of neoadjuvant PD-1 blockade monotherapy with toripalimab in elderly patients with
 locally advanced resectable esophageal squamous cell carcinoma (ESCC).
ICD-10 Classifications
Data Source
ClinicalTrials.gov
NCT06385730
Non-Device Trial